Business
Long-Term Expression of LentiVector
Long-Term Expression of LentiVector.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 4057X Oxford Biomedica PLC 06 May 2016 \n\n \n \n \n \n \n \nOxford BioMedica Presents Ground-Breaking Evidence of Long-Term Duration of Therapeutic Expression in Patients from its Proprietary LentiVector® Gene Delivery Platform \n \n \n \nOxford, UK - 6 May 2016: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Company\") (LSE:OXB), a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term four-year sustained and, in one of the studies, dose-dependent gene expression with the Company's LentiVector® delivery platform.\nOn 5 May 2016, Professor Stéphane Palfi presented a poster on OXB-101, a gene therapy product for the treatment of Parkinson's disease (PD), at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington DC, USA. In the Phase I/II study 15 advanced PD patients were treated with OXB-101 in three dose cohorts. OXB-101 demonstrated a favourable safety profile and a statistically significant improvement in motor function relative to baseline at six and 12 months post-treatment. The most recent follow-up data, presented this week, shows that the majority of patients continue to experience improvement in motor function relative to baseline over the four years since treatment. The Company has since developed OXB-102, a more potent version of OXB-101, and is planning to start a Phase I/II study in mid-2016. OXB-102 is Oxford BioMedica's gene therapy product that utilises its proprietary LentiVector® delivery platform to transfer three genes for dopamine synthesis in the striatum.\nIn addition, on 4 May 2016, Dr Andreas Lauer gave an oral presentation on Oxford BioMedica's LentiVector®-based treatment for neovascular age-related related macular degeneration (wet AMD), at the Association for Research in Vision and Ophthalmology (ARVO) conference in Seattle, USA. Consistent with results previously announced at the ARVO conference, the new data presented demonstrates that LentiVector® gene expression was dose-dependent and continued without significant decline for more than four years.\n \nCommenting on the new emerging data, John Dawson, Chief Executive Officer of Oxford BioMedica, said: \"We are very encouraged by the de...